Derbyshire Medicines Management and Clinical Policies
RED: Use in a combination regimen with ivacaftor for the treatment of cystic fibrosis in patients aged ≥6 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene. (Decision date - March 2022)
RED: SSC2587: for patients aged 2- 5 years with cystic fibrosis and homozygous for F508del mutation, or F508del heterozygous combined with any other mutation as per NHSE commissioning intentions. (Decision date - January 2024)
